Clinical Trials Logo

Complement Abnormality clinical trials

View clinical trials related to Complement Abnormality.

Filter by:
  • None
  • Page 1

NCT ID: NCT05258643 Recruiting - Covid19 Clinical Trials

The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study

TONIC
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection. Sample storage and subsequent use in fundamental research will be performed at VUB Neuro-Aging and Viro-Immunotherapy. Additionally, medical records of UZ Brussel will be searched and epidemiological, clinical, radiological, and biological data of the selected patients will be obtained at the diagnosis time point and during follow-up. Healthy volunteers will be recruited as well in the current study, as a comparison arm, after informed consent is obtained.

NCT ID: NCT04725812 Terminated - Pregnancy Related Clinical Trials

Complement Regulation to Undo Systemic Harm in Preeclampsia

CRUSH
Start date: September 13, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.

NCT ID: NCT04183101 Recruiting - C3 Glomerulopathy Clinical Trials

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereby attenuate renal disease and stabilize or improve kidney function and compare it to the currently used treatment with the angiotensin converting enzyme inhibitor, enalapril, in patients with the complement-mediated renal disease C3 glomerulopathy. Patients will be randomized to one or the other treatment for the first 6 months and then switch to the other treament for the following 2.5 years. Treatment will continue for altogether 3 years for each patient.

NCT ID: NCT04103489 Completed - Preeclampsia Severe Clinical Trials

The Use of Eculizumab in HELLP Syndrome

Start date: February 23, 2021
Phase: Phase 1
Study type: Interventional

This research study is being performed to see if women diagnosed with early preterm Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) syndrome (estimated gestational ages of 23-30 weeks) benefit from a medication called eculizumab (ECU). This drug blocks a part of the immune system called complement. By blocking this part of the immune system, eculizumab may stop or reverse the progression of the HELLP syndrome disease. The investigators will also look to see if this drug is effective and benefits both the mother and fetus.